课题基金 / 基金详情

Development of antimalarial histone deacetylase inhibitors

Development of antimalarial histone deacetylase inhibitors
抗疟组蛋白脱乙酰酶抑制剂的开发
批准号:
nhmrc : GNT1093378
负责人:
Prof David Fairlie
金额:
$55.68万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Development Grants
财政年份:
2015
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2015-01-01 至 --

项目摘要

项目成果

Prof David Fairlie的其他基金

相似基金

相关文献

中文摘要
翻译
人组蛋白去乙酰化酶(hdac)是临床证实为癌症化疗靶点的酶。不同的HDAC酶对传染性生物的生存很重要,比如引起疟疾的原生动物疟原虫。该项目将通过在小鼠身上进行临床前研究,开发有希望的药物线索,在不损害人体细胞的情况下杀死寄生虫,以实现未来治疗人类疟疾的临床试验。
英文摘要
Human histone deacetylases (HDACs) are enzymes clinically validated as targets for cancer chemotherapy. Different HDAC enzymes are important for survival of infectious organisms, such as protozoan Plasmodium parasites that cause malaria. This project will develop promising drug leads that kill the parasites without damaging human cells through preclinical studies in mice towards a future clinical trial for the treatment of malaria in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Super-resolution platform to accelerate biological and molecular research
  • 批准号:
    LE240100134
  • 项目类别:
    Linkage Infrastructure, Equipment and Facilities
  • 资助金额:
    $53.09万
  • 财政年份:
    2024
  • 负责人:
    Prof David Fairlie
  • 依托单位:
Compressing small peptides for cell absorption
  • 批准号:
    DP180103244
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $40.43万
  • 财政年份:
    2018
  • 负责人:
    Prof David Fairlie
  • 依托单位:
Combating infectious diseases by harnessing macrophage functions
  • 批准号:
    nhmrc : GNT1125316
  • 项目类别:
    Project Grants
  • 资助金额:
    $68.82万
  • 财政年份:
    2017
  • 负责人:
    Prof David Fairlie
  • 依托单位:
Modulating Protein-Protein Interactions In Disease
  • 批准号:
    nhmrc : GNT1117017
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $86.39万
  • 财政年份:
    2017
  • 负责人:
    Prof David Fairlie
  • 依托单位:
海外基金